|
| | | | |
| | | |
| Stat |
Members: 3645
Articles: 2'504'585
Articles rated: 2609
25 April 2024 |
|
| | | | |
|
Article overview
| |
|
|
Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules | | Byung-Je Sung
; Kwang Yeon Hwang
; Young Ho Jeon
; J I Lee
; Yong-Seok Heo
; Jin Hwan Kim
; Jinho Moon
; Jung Min Yoon
; Young-Lan Hyun
; Eunmi Kim
; Sung Jin Eum
; Sam-Yong Park
; Jie-Oh Lee
; Tae Gyu Lee
; Seonggu Ro
; Joong Myung Cho
; | | Rating: | Members: 4/5 (1 reader) | | Date: |
4 Sep 2003 | | Journal: | Nature, 425 (6953), 98-102 | | Abstract: | Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cyclic AMP and cyclic GMP. As essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction. Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction. Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available. Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacological profiles. | | Source: | PubMed, pmid12955149 doi: 10.1038/nature01914 | | Services: | Forum | Review | Favorites | |
|
|
1 review found:
(To access fulltext of a review, click on titles below.)
1. Science-advisor.net review 16090070 (1 reader) 
Rate this comment. |  | | | Review title: |
The head of the World Best Cure | | Reviewer: |
reviewer1919 | | Date: |
09 September 2016 at 20:16 GMT. | | Comment: | I aim and engage on essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction better research on www.comprarviagras.com |
|
|
| |
|
|
|
|
News, job offers and information for researchers and scientists:
| |
REGISTER